CR10099A - Inmunoglobulinas dirigidas contra nogo - Google Patents

Inmunoglobulinas dirigidas contra nogo

Info

Publication number
CR10099A
CR10099A CR10099A CR10099A CR10099A CR 10099 A CR10099 A CR 10099A CR 10099 A CR10099 A CR 10099A CR 10099 A CR10099 A CR 10099A CR 10099 A CR10099 A CR 10099A
Authority
CR
Costa Rica
Prior art keywords
directed against
immunoglobulins directed
against nogo
nogo
immunoglobulins
Prior art date
Application number
CR10099A
Other languages
English (en)
Inventor
Stephanie Jane Clegg
Jonathan Henry Ellis
Volker Germaschewski
Paul Andrew Hamblin
Ruth Mcadam
Rabinder Kumar Prinjha
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10099(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR10099A publication Critical patent/CR10099A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos para NOGO, formulaciones farmcéuticas que lo contienen y al uso de estos anticuerpos en el tratamiento y/o profilaxis de enfermedades o trastornos neurológicos.
CR10099A 2005-12-16 2008-06-20 Inmunoglobulinas dirigidas contra nogo CR10099A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins

Publications (1)

Publication Number Publication Date
CR10099A true CR10099A (es) 2008-09-22

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10099A CR10099A (es) 2005-12-16 2008-06-20 Inmunoglobulinas dirigidas contra nogo

Country Status (31)

Country Link
US (2) US8362208B2 (es)
EP (2) EP1960429B1 (es)
JP (1) JP5015949B2 (es)
KR (1) KR101355118B1 (es)
CN (1) CN101374863B (es)
AR (1) AR057239A1 (es)
AU (1) AU2006325228B2 (es)
BR (1) BRPI0619855A2 (es)
CA (1) CA2633501C (es)
CR (1) CR10099A (es)
CY (1) CY1113094T1 (es)
DK (1) DK1960429T3 (es)
EA (1) EA015536B1 (es)
ES (1) ES2389380T3 (es)
GB (1) GB0525662D0 (es)
HK (1) HK1119720A1 (es)
HR (1) HRP20120684T1 (es)
IL (1) IL192086A0 (es)
JO (1) JO2795B1 (es)
MA (1) MA30041B1 (es)
MY (1) MY149492A (es)
NO (1) NO20082699L (es)
NZ (1) NZ569143A (es)
PE (1) PE20071099A1 (es)
PL (1) PL1960429T3 (es)
PT (1) PT1960429E (es)
SI (1) SI1960429T1 (es)
TW (1) TWI378940B (es)
UA (1) UA96279C2 (es)
WO (1) WO2007068750A2 (es)
ZA (2) ZA200805111B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2513697C2 (ru) * 2007-11-02 2014-04-20 Новартис Аг Улучшенные молекулы, связывающиеся с nogo-а и их фармацевтическое применение
EP3045475B1 (en) 2008-04-02 2017-10-04 MacroGenics, Inc. Bcr-complex-specific antibodies and methods of using same
EP2271323A2 (en) 2008-05-06 2011-01-12 Glaxo Group Limited Encapsulation of biologically active agents
US20110268729A1 (en) * 2008-07-11 2011-11-03 Bams Abila Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
KR20150036398A (ko) 2012-07-05 2015-04-07 글락소 그룹 리미티드 근육위축가쪽경화증의 치료에서의 항­ｎｏｇｏ­ａ 항체의 최적 투여 섭생
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
WO2018232144A1 (en) * 2017-06-14 2018-12-20 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
MX2022004737A (es) 2019-10-24 2023-02-16 Novago Therapeutics Ag Anticuerpos anti-nogo-a novedosos.
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
WO2022263864A1 (en) 2021-06-17 2022-12-22 Petmedix Ltd Anti canine cd20 antibodies
KR20240099321A (ko) 2021-10-21 2024-06-28 펫메딕스 리미티드 P75ntr의 세포외 도메인을 포함하는 단백질
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
WO2023152486A1 (en) 2022-02-09 2023-08-17 Petmedix Ltd Therapeutic antibodies
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
GB202217993D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
PL186665B1 (pl) 1994-05-27 2004-02-27 Smithkline Beecham Spa Pochodne chinoliny jako antagoniści receptorów NKtachykininy, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca pochodne chinoliny oraz ich zastosowanie
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
DE69633336T2 (de) 1995-06-27 2005-09-22 Research Foundation Of Cuny Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP2264174A3 (en) 1998-07-22 2012-03-07 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding CDNA
CZ304224B6 (cs) 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
BRPI0417959A (pt) * 2003-12-22 2007-03-27 Glaxo Group Ltd anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável
AU2005207003C1 (en) * 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor

Also Published As

Publication number Publication date
SI1960429T1 (sl) 2012-09-28
UA96279C2 (ru) 2011-10-25
EA200801343A1 (ru) 2008-12-30
WO2007068750A2 (en) 2007-06-21
US20130287781A1 (en) 2013-10-31
ZA200906162B (en) 2010-05-26
CA2633501C (en) 2015-03-31
EP1960429B1 (en) 2012-06-27
TWI378940B (en) 2012-12-11
EP2228391A2 (en) 2010-09-15
BRPI0619855A2 (pt) 2011-10-25
JO2795B1 (en) 2014-03-15
JP5015949B2 (ja) 2012-09-05
CY1113094T1 (el) 2016-04-13
CA2633501A1 (en) 2007-06-21
ZA200805111B (en) 2009-12-30
EP1960429A2 (en) 2008-08-27
HK1119720A1 (en) 2009-03-13
MA30041B1 (fr) 2008-12-01
PL1960429T3 (pl) 2012-11-30
KR101355118B1 (ko) 2014-02-06
HRP20120684T1 (hr) 2012-09-30
CN101374863B (zh) 2013-05-29
NO20082699L (no) 2008-09-08
MY149492A (en) 2013-09-13
ES2389380T3 (es) 2012-10-25
AU2006325228B2 (en) 2011-12-15
PE20071099A1 (es) 2007-11-22
WO2007068750A3 (en) 2007-11-29
AR057239A1 (es) 2007-11-21
US8362208B2 (en) 2013-01-29
TW200801038A (en) 2008-01-01
IL192086A0 (en) 2008-12-29
EP2228391A3 (en) 2010-12-29
PT1960429E (pt) 2012-09-25
JP2009519025A (ja) 2009-05-14
EA015536B1 (ru) 2011-08-30
DK1960429T3 (da) 2012-09-24
CN101374863A (zh) 2009-02-25
NZ569143A (en) 2011-08-26
GB0525662D0 (en) 2006-01-25
KR20080080644A (ko) 2008-09-04
AU2006325228A1 (en) 2007-06-21
US20100221260A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
AR048912A1 (es) Inmunoglobulinas anti-nogo
ECSP088804A (es) Antagonistas de los piridil amida de los canales de calcio de tipo t
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
ECSP066559A (es)
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
UY29417A1 (es) Agentes endoparasiticidas
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CL2004000535A1 (es) Composicion farmaceutica que comprende rapamicina o un derivado de rapamicina y pimecrolimus; y su uso para el tratamiento de enfermedad inflamatoria del intestino.
HN2003000104A (es) Derivados de ciclopenteno
CR7835A (es) Uso de levocetiricina para el tratamiento de la rinitis alergica persistente
BRPI0516832A (pt) uso para alfa-simpatomiméticos com uma estrutura de 2-imidazolina
DOP2003000617A (es) Derivados de ciclopenteno
DOP2003000696A (es) Debencenoxazepinas